{"product_id":"global-gene-therapy-for-age-related-macular-degeneration-market-growth-status-and-outlook-2023-2029","title":"Global Gene Therapy for Age-related Macular Degeneration Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Gene Therapy for Age-related Macular Degeneration Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nMacular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular\/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Gene Therapy for Age-related Macular Degeneration Industry Forecast” looks at past sales and reviews total world Gene Therapy for Age-related Macular Degeneration sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy for Age-related Macular Degeneration sales for 2023 through 2029. With Gene Therapy for Age-related Macular Degeneration sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for Age-related Macular Degeneration industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Gene Therapy for Age-related Macular Degeneration landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy for Age-related Macular Degeneration portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for Age-related Macular Degeneration market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for Age-related Macular Degeneration and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for Age-related Macular Degeneration.\u003c\/p\u003e\n\n\u003cp\u003eThe global Gene Therapy for Age-related Macular Degeneration market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eIt has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for Age-related Macular Degeneration market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nSubretinal\u003cbr\u003e\nIntravitreal\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nMonotherapy\u003cbr\u003e\nCombination Therapy\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nRetroSense Therapeutics\u003cbr\u003e\nREGENXBIO\u003cbr\u003e\nAGTC\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 62 Pages \/ MCW16227490","offer_id":47645962895666,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-gene-therapy-for-age-related-macular-degeneration-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}